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Abstract Rheumatoid arthritis (RA) is an autoimmune dis-
ease characterized by abnormal prevalence of Th1, Th2,
Th17, and regulatory (Treg) subsets. Some data suggest that
these subsets are influenced by anti-RA agents. Follow-up
studies monitoring T cell phenotype in response to therapy
are limited. We investigated the alteration of CD4+ T cell
subset distribution after the initiation of disease-modifying
antirheumatic drug (DMARD) (with glucocorticosteroid
(GCS) and methotrexate (MTX)) and anti-TNFα therapy.
We enrolled 19 treatment naive (early) RA patients and initi-
ated GCS (in a dose of 16 mg/day for 4 weeks; then 8 mg/
day). MTX, 10 mg/week, was started at week 4. We also
enrolled 32 RA patients unresponsive to DMARD and initi-
ated anti-TNFα therapy: adalimumab (ADA), 40mg/2 weeks,
n=12; etanercept (ETA), 50 mg/weeks, n=12; or infliximab
(IFX) on week 0, 2, and 6, 3 mg/kg bw, n=8. Blood was taken
before and 4 and 8 weeks after the initiation of therapy. Ten
volunteers served as controls. The T cell phenotype was
assessed with flow cytometry. In early RA, Th1, Th2, and
Th17 prevalence was higher, while Treg prevalence was lower
than normal. GCS alone decreased Th2 prevalence. GCS +
MTX decreased Th17 prevalence. Immune phenotype in
unresponsive RA before anti-TNF therapy was as in early
RA. Four and 8 weeks after initiating anti-TNF therapy, Th1
prevalence was higher than baseline in ETA or IFX, while it
was stable in ADA groups. Th2 prevalence was higher than
normal in ADA or IFX, while normalized in ETA group. In
each group, Treg prevalence increased, while Th17 preva-
lence was at the baseline. The proinflammatory immune phe-
notype is normalized only under GCS +MTX combination in
early RA. Anti-TNFα therapy exhibit marked effects on all
the cell populations investigated (except Th17); some slight
differences in this action exist between ADA, ETA, and IFX
therapy.
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Introduction
Rheumatoid arthritis (RA) is the most common chronic
autoimmune joint disease, affecting approximately 0.5–
1 % of the adult population in industrialized countries [1,
2]. Various genes, environmental factors, autoantigens, and
still undefined factors play important roles in the patholog-
ical events that give rise to the systemic activation of the
immune system [3]. The abnormal functioning of CD4+
cells plays a key role in autoimmune process leading to the
development of RA. This is reflected by a number of obser-
vations indicating that the prevalence of different CD4+ sub-
sets responsible for the harmonized immune response is
skewed to a proinflammatory direction. The prevalence of
Th1, Th2 helper, and proinflammatory Th17 cells is increased
[4, 5], while that of regulatory Tcells (Treg) is decreased in the
peripheral blood of RA patients [6].
The release of inflammatory cytokines, particularly TNFα,
and the activation of proteases triggers an inflammatory cas-
cade culminating in chronic inflammation of the synovium, to
synovial hyperplasia, and eventually to the destruction of
cartilage and bone [7]. Based on the central role of TNFα
and other cytokines in disease's pathogenesis, biologic thera-
pies, respectively, a novel class of antirheumatic agents, were
approved for and are used effectively in patients with RA
unresponsive to conventional disease-modifying antirheumatic
drugs (DMARD) therapies.
Biologic therapies target different elements in autoimmune
process. Currently, infliximab, etanercept, and adalimumab,
the most commonly used biologic agents in RA are antibodies
(infliximab, adalimumab) and soluble receptors (etanercept)
that prevent the binding of TNFα to its receptor and inhibit its
inflammatory action. These agents are regarded as therapeu-
tically equivalent clinical alternatives in RA. However, there
are still some slight differences in their action, individual
responses, and side effect profile [8, 9].
Several types of conventional DMARD and biological
antirheumatic drugs have been demonstrated to influence
the T cell subset distribution, and it is increasingly ac-
knowledged that this action may contribute to the therapeu-
tic effects of such drugs [10]. However, follow-up studies
monitoring the changes in T cell subset distribution in
response to conventional and biological DMARD therapies
are limited at present. Moreover, no data are available as to
whether the effects on T cell subset distribution differ
between individual anti-TNFα agents. We have, therefore,
performed a comprehensive follow-up investigation of T
cell phenotype in RA patients before and during the
administration of synthetic DMARDs and adalimumab
(ADA), etanercept (ETA), and infliximab (IFX), three dif-
ferent anti-TNFα agents.
Patients and methods
Nineteen patients with newly diagnosed (treatment naive) RA
and 32 RA patients unresponsive to standard DMARD ther-
apy were enrolled into the study. The detailed clinical data and
patient's characteristics are presented in Table 1.
Treatment naive, early RA patients had not received any
anti-RA treatment prior to our study. After establishment of the
diagnosis, DMARD therapy was initiated according to a fixed
protocol as follows: medium-dose oral glucocorticosteroid
(GCS, 16 mg/day methylprednisolone) alone for 4 weeks;
GCS was subsequently tapered to 8 mg/day, and on week 4,
methotrexate (MTX) was started at 10 mg/week. Blood sam-
ples were taken before the initiation of DMARD therapy
(baseline), then after 4 and 8 weeks of treatment (i.e., after
4 weeks on medium-dose GCS and after a further 4 weeks of
combination therapy with low-dose GCS + MTX).
In the group of patients with established RA (n=32) not
responding to standard DMARD combination therapy (MTX
at 15 mg/week and leflunomide (LF) at 20 mg/day), anti-
TNFα therapy was initiated following the standard-of-care
decision of the treating physician: ADA at 40 mg/2 weeks
sc, n=12; ETA at 50mg/weeks sc, n=12; or IFX onweek 0, 2,
and 6 at 3 mg/kg iv, n=8. Blood samples were taken before the
initiation of each anti-TNFα agent, and on week 4 and 8 of
therapy. The patients receiving anti-TNF therapy were a ho-
mogenous group, including baseline clinical characteristics
(age, gender, disease duration, DAS-28 index, CRP, ESR,
rheumatoid factor, and anti-MCV status) and medication.
Established RA patients were all on long-term methotrexate
and leflunomide combination treatment (approximately
3 months), and none of them received glucocorticosteroids
or other immunosuppressive agents (Table 1).
Ten age- and gender-matched healthy volunteers served as
controls. All of them had a negative history of RA symptoms
and a negative status upon detailed physical and laboratory
examination. Written informed consent was obtained in ad-
vance from all participants. The project was approved by the
ethical committee of the University of Szeged (ETT-TUKEB
905/PI/09). This study was conducted in full accordance with
the tenets of Declaration of Helsinki (1964).
Five milliliter of lithium–heparin-anticoagulated blood
was taken from all participants for the identification of
CD4+ cell subsets. PBMCs were separated by gradient
centrifugation with Ficoll-Paque (GE Healthcare Life Sci-
ences, Pittsburgh, PA, USA), washed twice with phosphate-
buffered saline pH 7.4, and used for cell surface staining
with fluorescent antibodies (Becton Dickinson, San Diego,
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CA, USA) against cell surface markers according to the
manufacturer's instructions. Samples were measured within
1 h after staining; at least 300,000 events were recorded for
each acquisition.
Cell subtypes were defined as helper T cells (CD4+), Th1
cells (CD4+CXCR3+), Th2 cells (CD4+CCR4+), Th17 cells
(CD4+CCR4+CCR6+), regulatory T cells (Tregs; CD4+
CD25+CD127-), naive T cells (CD4+CD45RA+), or memory
T cells (CD4+CD45RO+). The prevalence values of CD4+
cells expressing early or late activation markers (i.e., CD69
and HLA-DR, respectively) were also determined [11].
All measurements were performed on a BD FACSAria
flow cytometer (Becton Dickinson, San Jose, CA, USA). Cell
prevalence values were determined with conventional gating,
through the use of FACSDiva software (Becton Dickinson,
San Jose, CA, USA).
The Mann–Whitney test was applied for the comparison of
the data on the controls and the patients, while the paired data in
each related patient group were compared by the Friedman test.
When the Friedman test demonstrated significant differences,
the post hoc Dunn test was used to identify which pairs were
significantly different. Levels of p<0.05 were taken as statisti-
cally significant. The clinical data in Table 1 are given as
means±SD, while the results in Tables 2 and 3 are expressed
as medians (interquartile range).
Results
Treatment naive, early RA patients exhibited higher than
normal Th1, Th2, and Th17 cell and lower than normal
Treg cell prevalence values (Table 2, Fig. 1). The prev-
alence of T cells expressing early or late activation
markers (CD69 and HLA-DR, respectively) and memory
cells were also higher than normal (Table 2). On week
4 of GCS treatment, the Th2 prevalence decreased sig-
nificantly, and, therefore, Th1/Th2 ratio shifted to the
Th1 direction, while the prevalence of activated T cells
expressing CD69 and HLA-DR markers normalized. At
this point, Th1, Th17, Tregs, memory, or naive cells
prevalence values were comparable to the baseline. By
week 8 (4 weeks after the initiation of MTX therapy
and start of the tapering of GCS), Th17 prevalence
decreased but was still higher than normal. It was note-
worthy that the Th2 cell prevalence returned to that on
week 4, whereas the other cell prevalence values remained
unaltered.
In DMARD, non-responders Th1, Th2, and Th17
prevalence values were higher, while Treg prevalence
was lower than normal at baseline (i.e., before the
initiation of anti-TNFα therapy). For details, see Table 3,
Fig. 2. Activated (i.e., CD69 and HLA-DR positive)
CD4+ cell prevalence was normal. Par hazard, baseline Ta
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naive/memory cell ratios markedly differed in patient
subgroups to be treated with the different anti-TNFα
agents. T cell subset distribution markedly altered under
anti-TNFα therapy with some differences between ETA,
ADA, and IFX subpopulations. By weeks 4 and 8, Th1
prevalence increased further in ETA or IFX patients,
while it was constant in ADA patients. Th2 prevalence
was constantly higher than normal under ADA or IFX
therapy, while normalized in patients treated with ETA.
Anti-TNFα therapy did not affect Th17 prevalence,
while it increased (but still not normalized) Treg prev-
alence, irrespectively of the anti-TNFα agent used.
(However, ADA patients exhibited a further increase in
Tregs by week 8, while Treg values were comparable to
those at week 4 in ETA and IFX patients). Activated
CD4+ prevalence values showed great variation according
to anti-TNFα agent used. Compared to the baseline, HLA-
DR+ prevalence increased in ADA patients on week 4 and
on week 8 in ETA patients, while remaining unaltered in
IFX patients. Of note, naive/memory cell ratio (also indi-
cating immunoactivation) also increased in ADA and ETA
but remained stable in IFX patients.
Discussion
This is the first study providing a longitudinal follow-up of the
prevalence of CD4+ cell subsets during different RA treat-
ment protocols and comparing the effects of commonly used
anti-TNFα agents on CD4+ phenotypes.
In treatment naive early RA patients, the distribution of the
major T lymphocyte subsets responsible for the regulation of
the immune response are shifted to a proinflammatory status.
We demonstrated increased prevalence of circulating Th1 and
Th2 lymphocytes, indicating an overall activation of the im-
mune system. This is in line with previous data pointing to RA
being a Th1-dominant disease [12] even in the presence of
high Th2 numbers [5].
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A dynamic balance between proinflammatory and antiinfla-
mmatory forces is crucial in healthy immune homeostasis. As
major suppressors of the immune system, Tregs have been at
the center of attention for more than a decade, but in recent
years, IL-17-producing proinflammatory Th17 cells have also
emerged as playing an important role in this balance [13]. Their
predominance may contribute to inflammation, cartilage de-
struction, and bone erosion in RA [14]. Similarly to other
studies [15, 16], we observed an increase in the prevalence of
Th17 cells, while that of Tregs was decreased in RA. The net
effect of the shift in the Th17/Treg ratio in a proinflammatory
direction is the increased activation of T lymphocytes. Our
findings concerning the immune phenotype support this notion,
as the prevalence of cells expressing any of the activation
markers tested proved to be increased in RA.
CD69, an early activation marker, is known to trigger local
inflammatory responses in RA [17]. A high number of CD69-
expressing T cells were earlier detected in the RA synovium
[18]. We have now demonstrated that the prevalence of
CD69+ T cells in the peripheral blood of RA patients was
higher than normal. Another change indicating a systemic
immune activation in RAwas that, in addition to the increased
CD69 level, the prevalence of HLA-DR+ cells was also
increased in our patients. This is in line with the finding of
Afeltra et al. that the HLA-DR expression changes together
with that of CD69 on RAT lymphocytes [19]. A further sign
of an activated immune status in RA is the transition from
naive to memory cells [20], as reflected by the decreased ratio
of naive/memory T cells that we observed in the peripheral
blood of the RA patients.
These observations support the view that the immune system
exhibits a systemic dysregulation in RA. As treatment naive
RA patients in this study apparently did not suffer from extra-
articular complications, our findings indicate that abnormalities
in the immune phenotype in the peripheral blood may precede
the progression of RA from a local to a systemic disease.
Interestingly, the therapy of early RAwith oral GCS did not
induce major changes in the tested CD4+ subgroup preva-
lence. After 4 weeks of treatment with GCS, the only marked
change in T cell subgroup prevalence was the decrease in the
prevalence of Th2 cells (It should be noted that an analogous
effect of GCS on the peripheral blood immune phenotype was
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reported in patients with bronchial asthma [21]). In turn, the
prevalence of Tregs, Th17, and Th1 remained stable at this
point. This results in a skewing towards Th1 in the Th1/Th2
ratio. In light of the Th1 cytokine actions, therefore, this effect
can be regarded as a proinflammatory stimulus. This constel-
lation is present in spite of the fact that the inflammatory signs
and symptoms associated with RA still improved in the pa-
tients (decreases in the T cells expressing early or late activa-
tion parameters). This contradiction may indicate a chronic
inflammatory stimulus which under successful treatment does
not reach the threshold of clinical symptoms. This indicates
that the therapeutic effects of GCS in RA are not reflected in
systemic distribution of Th1, Th2, Treg, and Th17 cells.
Later, with the gradual tapering of the GCS therapy and the
introduction of MTX, at week 8, we observed an increase in
the prevalence of Th1 and Th2 cells, while that of Th17 cells
decreased. Our data do not allow a decision as to whether the
tapering of the GCS dose and/or the administration of MTX is
responsible for the altered immune phenotype. Both options
appear reasonable. While it is known that GCS therapy may
decrease the Th2 prevalence, it seems logical to postulate that
its withdrawal may lead to an increase in this cell population,
and this is supported by our results. Data have been published,
suggesting that MTX monotherapy may increase the Th2
prevalence [22] (albeit the prevalence of Th1 cells was also
decreased, which was not observed in our study).
It is difficult to compare our results on the prevalence of
Tregs with those of other studies, as the markers used for the
identification of Tregs have gone through a major evolution in
the past decade. These cells were first described as CD4+
CD25+ [23], but later as CD4+CD25high [24], and they were
subsequently identified according to their FoxP3 expression
(CD4+CD25+FoxP3+) [25].More recently, it has been shown
that the absence of CD127 expression can be used as an
alternative to the transcription factor FoxP3 [26], and it is also
generally accepted that CD127 inversely correlates with
FoxP3 in CD4+ cells [27]. For technical reasons, we defined
Tregs as cells exhibiting the CD4+CD25+CD127-phenotype.
We found no changes in the prevalence of Tregs during MTX
therapy, which confirms previous results on CD4+CD25high
Tregs [28] and CD4+CD25+FoxP3+ Tregs [29], showing that
MTX has no direct action on this feature in RA patients.
The situation revealed by the available literature as con-
cerns the effect of MTX on Th17 cells is also confusing.
During in vitro experiments, Li et al. did not find any changes
in the percentage of Th17 cells in response to MTX treatment
[30], and other authors too reported that MTX monotherapy
left this parameter unchanged after 12 weeks [29] and after
30 weeks [31] in patients with RA. However, the study byYue
et al. indicated that after 12 weeks of MTX treatment, the
prevalence of Th17 cells was decreased in patients with RA
[32]. Our results are the first to indicate a decrease in the
prevalence of Th17 cells in the peripheral blood of RA
patients following only 4 weeks of MTX treatment. It is
important to note, however, that in our study, we could not
differentiate between the effects of MTX alone and those of
the gradual withdrawal of GCS. It is also a matter of debate
whether this observed decrease in Th17 prevalence is transient
or is maintained for a longer period.
As the net result of GCS followed by MTX therapy, the cell
surface activation markers (CD69 and HLA-DR) became per-
sistently lower than the baseline after 2 months of immune
modulating therapy. We found no published data regarding the
expressions of activation markers in the peripheral blood (or in
the synovium) of RA patients during GCS or MTX treatment.
In RA patients who were unresponsive to conventional
DMARD treatment and who were candidates for anti-TNFα
therapy, the prevalence values of Th1, Th2, and Th17 cells
were as high as, and that of Treg cells was as low as, the
corresponding levels in newly diagnosed RA patients. While
this observation raises the possibility that the immune pheno-
type is comparably shifted to a proinflammatory status as in
early RA, the normal prevalence of activated T cells may
indicate that, despite the high proinflammatory cell preva-
lences, the overall activation state of the T cells is comparable
to that in the controls. The explanation of this apparent con-
tradiction is not clear. It should be noted, however, that, at this
time point, these patients had already been treated with MTX
and LF, which probably influenced the prevalences of the
activated T cell subtypes.
After 4 weeks of anti-TNFα therapy, the overall condition
of the patients was significantly improved in all of the exam-
ined groups. Again, the changes in immune phenotype did not
fully reflect the clinical status and were somewhat therapy
specific. After 4 weeks, there was a tendency to a higher Th1
cell prevalence in the ETA and IFX-treated patients, and it had
become significant after 8 weeks of therapy. This finding is in
line with the report of Aeberli et al. [4], who demonstrated an
increase in Th1 prevalence in patients who received 6 weeks
of ETA or IFX therapy. The shift in the Th1/Th2 ratio in the
Th1 direction became more significant in our ETA-treated
group in consequence of the simultaneous decrease in Th2
prevalence (which was not observed with IFX). Such an effect
on Th2 was not documented for ETA in the study of Aeberli
et al. The shift in the Th1 direction in the peripheral blood may
indicate the impact of the therapy on disease progression. It is
increasingly acknowledged that this shift is due to the selec-
tive recruitment of Th1 cells from the synovium, which re-
duces local inflammatory reactions in the joints [33, 34].
Interestingly, ADA left the Th1 and Th2 cell ratios intact in
our study. One can speculate whether this finding is due to the
different origin of the drug (i.e., ADA is a monoclonal anti-
body, while IFX and ETA are mouse–human chimeric pro-
teins and TNF receptor-IgG fusion proteins, respectively)
[35]. If this is the case, the effect of ETA and IFX on Th1/
Th2 ratio can be regarded rather as a consequence of their
182 Clin Rheumatol (2014) 33:175–185
structure and not as their effect on target molecule. This
speculation is seemingly worth to be investigated further.
The effects of anti-TNFα therapy on the prevalence of Th17
cells in RA have previously been investigated in a number of
studies. It has been shown that the level of Th17 cells in the
periphery of RA patients is reduced as a consequence of IFX
[31], ADA [32] or ETA [36] treatment. These observations
were made during a much longer follow-up period (12 and
30 weeks of treatment), while our data showed that none of the
three anti-TNFα therapies applied had no effect on Th17
prevalence after treatment for 4 or 8 weeks. Although we
detected a tendency to a decreased Th17 prevalence in the
ADA and IFX-treated groups, the lack of significant alterations
may indicate that more time is needed for these drugs to exert a
relevant effect on the Th17 cell prevalence.
On the other hand, the prevalence of Tregs was significant-
ly increased after only 4 weeks of anti-TNFα therapy in all of
the examined groups. Despite many studies, the impact of
anti-TNFα agents on Tregs in RA remains controversial.
Valencia et al. reported that IFX increased the expressions of
Foxp3 mRNA and protein in CD4+CD25high Tregs in RA
patients and restored their suppressive function that had pre-
viously been downregulated by TNFα [37]. Ehrenstein et al.
demonstrated that IFX increased CD4+CD25+ in the periph-
eral blood of RA patients, but only in those who responded to
IFX therapy; it was ineffective in the non-responders [38]. In
accordance with this, Lina et al. observed that the percentages
of CD4+CD25highFoxp3+ Tregs in RA patients were in-
creased after combined therapy with MTX and ETA [29].
Vigna-Pérez et al. found an increase in CD4+CD25high Tregs
on day 15 of ADA therapy, but this effect was only transient,
as it was diminished on day 180 [39]. In contrast, Blache et al.
reported that neither ADA nor ETA modified the percentages
or absolute numbers of circulating CD4+CD25high Tregs in
RA patients after 6 and 12 weeks of treatment [40]. In our
study, the ADA, ETA, and IFX groups consistently presented
increased Treg prevalence levels as compared with the base-
line, although they still remained lower than those in the
controls. Treg prevalence tended to increase further by week
8 in each group, though with a significant elevation only in the
ADA group. This seems to be a specific effect of ADA (it
should be noted, however, that the long-term effects of the
anti-TNFα agents used cannot be inferred from our results; in
the study by Vigna-Pérez, the effect of ADA on Tregs
disappeared by week 26 of therapy [39]).
We also tested the prevalences of T cell subtypes with a
different activation status. As described above, the decreased
ratio of naive/memory T cells indicate an overall activation of
the immune system in RA [20]. Interestingly, in general,
naive/memory T cell ratio was normal in RA (a remarkable
exception was the IFX-group that exhibited lower than normal
cell ratios. As this parameter was not used when patients were
subjected to any of the anti-TNFα agents, this baseline
heterogeneity is probably of chance). Of note, CD69 and
HLA-DR activation markers were also normal in all groups
(including IFX). The normal expression of CD4+ activation
markers in the presence of marked inflammation in RA may
indicate amild form of Tcell anergy in patients not responding
to conventional DMARD therapy.
This phenomenon has also been noted by others. It has
been explained by prolonged exposure to high TNFα levels
[41], as TNFα impairs the activation of the T cells through the
T cell receptor/CD3 complex in RA [42], but, in our patients,
the immune modulatory action of MTX (seen in treatment
naive patients) may also contribute.
Literature data suggest that Tcell anergy can also be reversed
by anti-TNFα treatment [41, 42]. Our results may indicate that
this reversing effect may depend on the anti-TNFα agent used.
In ADA patients, the ratio of naive/memory cells was signifi-
cantly decreased relative to the baseline after 4 weeks (due to
the increase of memory cell prevalence) and remained high at
week 8 in patients treated with ADA. In contrast, in ETA
patients, this ratio increased further by week 8 as compared
with the baseline. IFX had no effect on the ratio of naive/
memory cells at any time point in the studied period. Another
activation marker, HLA-DR, increased in ADA and ETA but
not in IFX patients at week 4, and remained high at week 8. The
mechanism behind the heterogeneity of the effect of different
anti-TNFα agents on CD4+ activation markers should be ex-
plored further. However, our finding may indicate that these
biological agents may provide different modulatory actions on
CD4+ cells in spite of comparable clinical efficacy.
Conclusions
This study on peripheral blood samples has provided compre-
hensive information regarding the impact of anti-RA therapy
on CD4+ cell distributions.
In early RA, the peripheral T cells are skewed to an acti-
vated status (due to low Treg and high Th1, Th2, and Th17
and to a high prevalence of activated T cell subtypes). This
skewing was not normalized by GCS administration, while
the introduction of MTX resulted in a lower activation status
by influencing mainly the prevalence of Th17 cells. The
abnormalities in DMARD-refractory RAwere comparable to
those in early RA. Anti-TNFα therapy exhibited major effects
on all the cell populations investigated (except Th17), with
some differences between ADA, ETA, and IFX therapy.
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